Injectable Octreotide Dosing for Hepatorenal Syndrome (HRS)
For acute variceal hemorrhage in cirrhotic patients, administer octreotide as a 50 mcg IV bolus followed by continuous infusion at 50 mcg/hour. This is the standard dosing regimen supported by FDA labeling and clinical evidence 1.
Initial Dosing Protocol
The recommended approach consists of two components:
- IV Bolus: 50-100 mcg administered as initial bolus
- Continuous Infusion: 25-50 mcg/hour for 24-72 hours
The FDA label specifically states octreotide may be given by rapid IV bolus in emergency situations, with the standard infusion rate being 50 mcg/hour 1. This can be diluted in 50-200 mL of sterile isotonic saline or dextrose 5% and infused over 15-30 minutes, or given as IV push over 3 minutes 1.
Evidence-Based Dosing Considerations
The 50 mcg/hour infusion rate demonstrates superior efficacy. Research comparing 50 mcg/hour versus 25 mcg/hour showed that while both doses reduce portal pressure during infusion, the higher dose maintains sustained pressure reduction after cessation, whereas the 25 mcg/hour dose returns to baseline 2. Portal pressure remained significantly lower in the 50 mcg/hour group at 24 hours (24.8 vs 29.4 mmHg) and 48 hours (25.3 vs 29.9 mmHg) after stopping infusion 2.
Clinical trials in acute variceal bleeding used 100 mcg bolus followed by 25 mcg/hour infusion with 88% initial bleeding control at 6 hours 3. Another study used 50 mcg bolus plus 50 mcg/hour infusion with 84% control rates 4. The higher infusion rate appears more rational for preventing rebleeding 2.
Duration of Therapy
- Standard duration: 24-72 hours of continuous infusion
- Extended therapy: May continue up to 5 days for post-sclerotherapy bleeding 5
- Dose escalation: If bleeding not controlled within 12 hours, add hourly 50 mcg boluses for 24 hours on top of continuous infusion 5
Important Caveats
Octreotide causes both hypoglycemia and hyperglycemia—insulin dosing adjustments may be necessary 6. Common adverse effects (>10% incidence) include bradycardia, cardiac conduction abnormalities, diarrhea, nausea, and hyperglycemia 6. These are generally dose-dependent but less severe than terlipressin or vasopressin alternatives 6.
Renal and hepatic impairment alter pharmacokinetics. In severe renal failure, clearance drops from 10 L/hr to 4.5 L/hr 1. In liver cirrhosis, half-life increases to 3.7 hours with clearance decreasing to 5.9 L/hr 1. However, the FDA label does not mandate dose adjustments for these conditions 1.
The drug is stable in saline or D5W for 24 hours but incompatible with TPN solutions due to glycosyl conjugate formation 1.